Drug-induced pemphigoid: A review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 9, 2014, Pages 1133-1140

  Stavropoulos, P G ^a   Soura, E ^a   Antoniou, C ^a  

^a ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALICYLIC ACID DERIVATIVE; TOPICAL AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VACCINE;

BULLOUS PEMPHIGOID; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INDUCED BULLOUS PEMPHIGOID; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; CHEMICALLY INDUCED; DRUG ERUPTIONS;

DRUG ERUPTIONS; HUMANS; PEMPHIGOID, BULLOUS;

EID: 84906936168     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12366     Document Type: Review

References (67)

1. Kasperkiewicz M, Zillikens D,. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.
2. Kalaaji NE, Nicolas MEO,. Linear basement membrane zone staining pattern. In, Kalaaji NE, Nicolas MEO, eds. Mayo Clinic Atlas of Immunofluorescence in Dermatology. Mayo Clinic Scientific Press, Taylor & Francis Group, Boca Raton, FL, 2006: 1-3.
3. Smith EP, Taylor TB, Meyer LJ, Zone JJ,. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993; 29 (5 Pt 2): 879-882.
4. Kashihara M, Danno K, Miyachi Y, Horiguchi Y, Imamura S,. Bullous pemphigoid-like lesions induced by phenacetin. Report of a case and an immunopathologic study. Arch Dermatol 1984; 120: 1196-1199.
5. Alcalay J, David M, Ingber A, Hazaz B, Sandbank M,. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol 1988; 18 (2 Pt 1): 345-349.
6. Hofmann M, Audring H, Sterry W, Trefzer U,. Interleukin-2-associated bullous drug dermatosis. Dermatology 2005; 210: 74-75.
7. Ruocco V, Sacerdoti G,. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-312.
8. Lee JJ, Downham T,. Furosemide induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006; 5: 562-564.
9. Bowman C, Delrieu O,. Immunogenetics of drug-induced skin blistering disorders. Part I: perspective. Pharmacogenomics 2009; 10: 601-621.
10. Ahmed AR, Mohimen A, Yunis EJ, et al,. Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993; 177: 419-424.
11. Park B, Sanderson J, Naisbitt D,. Drugs as haptens, antigens, and immunogens. In, Pichler WJ, ed. Drug Hypersensitivity. Karger, Basel, 2007: 55-65.
12. Patsatsi A, Vyzantiadis TA, Chrysomallis F, Devliotou-Panagiotidou D, Sotiriadis D,. Medication history of a series of patients with bullous pemphigoid from northern Greece-observations and discussion. Int J Dermatol 2009; 48: 132-135.
13. Newport MJ, Goetghebuer T, Marchant A,. Hunting for immune response regulatory genes: vaccination studies in infant twins. Expert Rev Vaccines 2005; 4: 739-746.
14. Baum H, Butler P, Davies H, Sternberg MJ, Burroughs AK,. Autoimmune disease and molecular mimicry: a hypothesis. Trends Biochem Sci 1993; 18: 140-144.
15. Ruocco V, de Luca M, Pisani M, de Angelis E, Vitale O, Astarita C,. Pemphigus provoked by D(-)penicillamine. An experimental approach using in vitro tissue cultures. Dermatologica 1982; 164: 236-248.
16. Bean SF, Good RA, Windhorst DB,. Bullous pemphigoid in an 11-year-old boy. Arch Dermatol 1970; 102: 205-208.
17. Vassileva S,. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998; 16: 379-387.
18. Bastuji-Garin S, Joly P, Picard-Dahan C, et al,. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996; 132: 272-276.
19. Lloyd-Lavery A, Chi Chi C, Wojnarowska F, Taghipour K,. The associations between bullous pemphigoid and drug use. A UK case-control study. JAMA Dermatol 2013; 149: 58-62.
20. Ameglio F, D'Auria L, Cordiali-Fei P, et al,. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents 1997; 11: 148-153.
21. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS,. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999; 79: 288-290.
22. Kennedy JS, Devillez RL, Henning JS,. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol 2010; 9: 68-70.
23. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP,. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006; 142: 1457-1461.
24. Heffernan MP, Bentley DD,. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006; 142: 1268-1270.
25. Nin M, Tokunaga D, Ishii N, Komai A, Hashimoto T, Katoh N,. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 2013; 40: 55-56.
26. Yamauchi PS, Lowe NJ, Gindi V,. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006; 54 (3 Suppl. 2): S121-S122.
27. Saraceno R, Citarella L, Spallone G, Chimenti S,. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 2008; 33: 154-155.
28. Cusano F, Iannazzone SS, Riccio G, Piccirillo F,. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol 2010; 20: 520.
29. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M,. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 2009; 219: 357-358.
30. Boussemart L, Jacobelli S, Batteux F, et al,. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010; 221: 201-205.
31. Stausbøl-Grøn B, Deleuran M, Sommer Hansen E, Kragballe K,. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 2009; 34: 285-286.
32. Duong TA, Buffard V, André C, et al,. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol 2010; 62: 161-162.
33. Monnier-Murina K, Du Thanh A, Merlet-Albran S, Guillot B, Dereure O,. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology 2009; 219: 89-90.
34. Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA,. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol 2007; 179: 4840-4848.
35. García-Doval I, Mayo E, Nogueira Fariña J, Cruces MJ,. Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain. Br J Dermatol 2006; 155: 820-823.
36. Lear JT, Tan BB, English JS,. Bullous pemphigoid following influenza vaccination. Clin Exp Dermatol 1996; 21: 392.
37. Fournier B, Descamps V, Bouscarat F, Crickx B, Belaich S,. Bullous pemphigoid induced by vaccination. Br J Dermatol 1996; 135: 153-154.
38. García-Doval I, Rosõn E, Feal C, De la Torre C, Rodríguez T, Cruces MJ,. Generalized bullous fixed drug eruption after influenza vaccination, simulating bullous pemphigoid. Acta Derm Venereol 2001; 81: 450-451.
39. Downs AM, Lear JT, Bower CP, Kennedy CT,. Does influenza vaccination induce bullous pemphigoid? A report of four cases. Br J Dermatol 1998; 138: 363.
40. Chacõn GR, Sinha AA,. Bullous pemphigoid after herpes zoster vaccine administration: association or coincidence? J Drugs Dermatol 2011; 10: 1328-1330.
41. Lohrisch I, Haustein UF, Baumert A, Szeskus H,. Immune response to tetanus toxoid in bullous pemphigoid. Dermatol Monatsschr 1985; 171: 153-157.
42. Hafiji J, Bhogal B, Rytina E, Burrows NP,. Bullous pemphigoid in infancy developing after the first vaccination. Clin Exp Dermatol 2010; 35: 940-941.
43. Baykal C, Okan G, Sarica R,. Childhood bullous pemphigoid developed after the first vaccination. J Am Acad Dermatol 2001; 44 (2 Suppl.): 348-350.
44. Mérida C, Martínez-Escribano JA, Frías JF, Sánchez-Pedreño P, Corbalán R,. Bullous pemphigoid in an infant after vaccination. Actas Dermosifiliogr 2005; 96: 255-257.
45. Valdivielso-Ramos M, Velázquez D, Tortoledo A, Hernanz JM,. Infantile bullous pemphigoid developing after hexavalent, meningococcal and pneumococcal vaccinations. An Pediatr (Barc) 2011; 75: 199-202.
46. Jedlickova H, Racovska J, Niedermeier A, Feit J, Hertl M,. Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus. Eur J Dermatol 2008; 18: 534-538.
47. Hirose M, Recke A, Beckmann T, et al,. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 2011; 187: 1176-1183.
48. Walmsley N, Hampton P,. Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid. J Dermatol Case Rep 2011; 5: 74-76.
49. Chiavérini C, Hamel-Teillac D, Gilbert D, De Prost Y,. Absence of anti-BP180 antibodies in mothers of infants with bullous pemphigoid. Br J Dermatol 2006; 54: 839-843.
50. Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D,. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011; 34: 133.
51. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID,. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249-253.
52. Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V,. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 2013; 149: 243-245.
53. Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP,. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate. Dermatol Online J 2012; 18: 9.
54. Nakatani K, Kurose T, Hyo T, et al,. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther 2012; 3: 14.
55. Andukuri R, Drincic A, Rendell M,. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes 2009; 2: 117-126.
56. Schmiedl A, Pabst R, Wagner L, et al,. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 2008; 181: 1120-1127.
57. Kruschinski C, Skripuletz T, Bedoui S, et al,. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 2005; 139: 17-24.
58. Thielitz A, Vetter RW, Schultze B, et al,. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 2008; 128: 855-866.
59. Langan SM, Groves RW, West J,. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-636.
60. Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z,. Bullous pemphigoid and internal diseases-a case-control study. Eur J Acad Dermatol Venereol 2010; 20: 96-101.
61. Li L, Chen J, Wang B, Yao Y, Zuo Y,. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343-1345.
62. Chorzelski T, Jablonska S, Beutner EH,. Bullous pemphigoid: relationship of immunopathology to clinical findings. In, Beutner EH, Chorzelski T, Bean SF, eds. Immunopathology of the Skin, 3rd edn. John Willey, New York, 1987: 337-352.
63. Soni BP, McAlvany JP, Fleischer AB, Sherertz EF,. Bullous pemphigoid mimicking contact dermatitis. Contact Dermatitis 1996; 35: 314.
64. Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G,. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 2012; 167: 1200-1214.
65. Diab M, Coloe J, Bechtel MA,. Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis 2009; 83: 139-140.
66. Aksakal BA, Ozsoy E, Arnavut O, Ali Gürer M,. Oral terbinafine-induced bullous pemphigoid. Ann Pharmacother 2003; 37: 1625-1627.
67. Kalińska-Bienias A, Rogoziński TT, Woźniak K, Kowalewski C,. Can pemphigoid be provoked by lisinopril? Br J Dermatol 2006; 155: 854-855.